Spero Therapeutics, Inc. (SPRO)
2.74
-0.06
(-2.14%)
USD |
NASDAQ |
Apr 24, 16:00
2.75
+0.01
(+0.36%)
After-Hours: 20:00
Spero Therapeutics Enterprise Value : 121.25M for April 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SIGA Technologies, Inc. | 173.24M |
| SELLAS Life Sciences Group, Inc. | 730.05M |
| Nephros, Inc. | 26.21M |
| ACADIA Pharmaceuticals, Inc. | 2.977B |
| Alnylam Pharmaceuticals, Inc. | 40.58B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 31.52M |
| Revenue (Quarterly) | 39.66M |
| Total Expenses (Quarterly) | 8.138M |
| EPS Diluted (Quarterly) | 0.5309 |
| Profit Margin (Quarterly) | 79.48% |
| Earnings Yield | 4.34% |
| Normalized Earnings Yield | 4.730 |